| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
Ingenol targets protein kinase C (PKC). It is a PKC activator with a Ki of 30 μM. By activating PKC, ingenol induces cell necrosis and stimulates local immune responses to promote the clearance of abnormal or tumor cells. It has a variety of biological effects, including apoptosis induction.
|
|---|---|
| ln Vitro |
PKC activator ingenol has a Ki of 30 μM. Primary mouse epidermal keratinocytes undergo morphological alterations and are exposed to 1 mM of ingenol, which also induces ornithine decarboxylase activity (1, 3 mM). Intercellular transmission is similarly inhibited by ingenol (125 μM, 250 μM, 500 μM, 1 mM) [1].
In vitro, ingenol is a PKC activator with a Ki of 30 μM. It induces ornithine decarboxylase activity (1, 3 mM) and causes morphological changes (1 mM) in primary mouse epidermal keratinocytes. Ingenol induces apoptosis in cancer cells. It has an ED50 value of 27 μM in vitro. |
| ln Vivo |
In vivo, ingenol mebutate, a derivative of ingenol, is an effective treatment for actinic keratosis. Ingenol activates the PKC signaling pathway, inducing cell necrosis and stimulating local immune responses. It has anti-tumor promotion activity. Ingenol esters may be used to reactivate latent HIV.
|
| Enzyme Assay |
The activity of ingenol can be assessed using PKC enzyme assays. PKC is incubated with its substrate and cofactors in the presence of varying concentrations of ingenol. The activation of PKC is measured by the phosphorylation of a peptide substrate. The Ki value for PKC activation is determined from dose-response curves.
|
| Cell Assay |
To evaluate the cellular effects of ingenol, keratinocytes or cancer cells are treated with the compound. The activation of PKC and downstream signaling pathways is assessed by Western blotting. Cell viability, apoptosis, and necrosis are measured using standard assays. Morphological changes are assessed by microscopy.
|
| Animal Protocol |
In vivo studies with ingenol typically involve topical application to the skin in models of actinic keratosis or skin cancer. The compound's effects on lesion clearance, immune cell infiltration, and tumor growth are assessed. In other models, its effects on HIV reactivation or other diseases can be evaluated.
|
| ADME/Pharmacokinetics |
Ingenol has a molecular formula of C20H28O5 and a molecular weight of 348.43. Its CAS number is 30220-46-3. The compound is a diterpenoid derived from the Euphorbia peplus plant. It is soluble in organic solvents. The purity is typically >98%.
|
| Toxicity/Toxicokinetics |
Specific toxicology data for ingenol are not detailed in the available literature. However, as a PKC activator, it can cause local irritation and inflammation. In clinical use, ingenol mebutate is applied topically and is generally well-tolerated, with local skin reactions being the most common side effect.
|
| References | |
| Additional Infomation |
Ingenol is a tetracyclic diterpenoid compound with the chemical formula 1a,2,5,5a,6,9,10,10a-octahydro-1H-2,8a-methylenecyclopentano[a]cyclopropano[e][10]cycloen-11-one, wherein hydroxyl groups are substituted at positions 5, 5a, and 6; methyl groups are substituted at positions 1, 1, 7, and 9; hydroxymethyl is substituted at position 4; and a carbonyl group is substituted at position 1 (diastereomers are 1aR,2S,5R,5aR,6S,8aS,9R,10aR). It is a tetracyclic diterpenoid compound and also a cyclic terpene ketone. Ingenol has been reported to exist in Euphorbia esula, Euphorbia helioscopia, and other organisms with relevant data.
Ingenol is a natural compound derived from the Euphorbia peplus plant. It is a PKC activator with antitumor activity. Its derivative, ingenol mebutate, is an effective treatment for actinic keratosis. Ingenol is also used as a research tool to study PKC signaling and cancer biology. |
| Molecular Formula |
C20H28O5
|
|---|---|
| Molecular Weight |
348.4333
|
| Exact Mass |
348.193
|
| CAS # |
30220-46-3
|
| Related CAS # |
Ingenol Mebutate;75567-37-2
|
| PubChem CID |
442042
|
| Appearance |
White to light yellow solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
523.8±50.0 °C at 760 mmHg
|
| Melting Point |
153 °C
|
| Flash Point |
284.7±26.6 °C
|
| Vapour Pressure |
0.0±3.1 mmHg at 25°C
|
| Index of Refraction |
1.625
|
| LogP |
2.95
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
25
|
| Complexity |
707
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
C[C@@H]1C[C@@H]2[C@@H](C2(C)C)[C@@H]3C=C([C@H]([C@]4([C@@]1(C3=O)C=C([C@@H]4O)C)O)O)CO
|
| InChi Key |
VEBVPUXQAPLADL-POYOOMFHSA-N
|
| InChi Code |
InChI=1S/C20H28O5/c1-9-7-19-10(2)5-13-14(18(13,3)4)12(17(19)24)6-11(8-21)16(23)20(19,25)15(9)22/h6-7,10,12-16,21-23,25H,5,8H2,1-4H3/t10-,12+,13-,14+,15+,16-,19+,20-/m1/s1
|
| Chemical Name |
(1S,4S,5R,6R,9S,10R,12R,14R)-4,5,6-trihydroxy-7-(hydroxymethyl)-3,11,11,14-tetramethyltetracyclo[7.5.1.01,5.010,12]pentadeca-2,7-dien-15-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~287.00 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.18 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.18 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.18 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8700 mL | 14.3501 mL | 28.7002 mL | |
| 5 mM | 0.5740 mL | 2.8700 mL | 5.7400 mL | |
| 10 mM | 0.2870 mL | 1.4350 mL | 2.8700 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
